The addition of netarsudil as an adjunctive treatment yielded further IOP lowering in patients with glaucoma enrolled in a phase 4 study.
The prospective, multicenter, open-label study showed that patients in a real-world setting who were treated with the once-daily Rho kinase (ROCK) inhibitor Rhopressa (netarsudil, Aerie Pharmaceuticals) achieved 4.3 mm Hg to 4.5 mm Hg of additional IOP reduction whether it was added to prior prostaglandin analogue (PGA) monotherapy or prior multi-drug therapy.
The study, dubbed M.O.S.T. (Multi-center Open-label Study), treated 260 subjects with primary
Uncategorized